摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Aethyl-tert.-butyl-formal | 25116-84-1

中文名称
——
中文别名
——
英文名称
Aethyl-tert.-butyl-formal
英文别名
2-ethoxymethoxy-2-methyl-propane;ethoxy-tert-butoxy-methane;Aethoxy-tert-butoxy-methan;Formaldehyd-aethyl-tert.-butyl-acetal;2-(Ethoxymethoxy)-2-methylpropane
Aethyl-tert.-butyl-formal化学式
CAS
25116-84-1
化学式
C7H16O2
mdl
——
分子量
132.203
InChiKey
YOIWVMGFWGMWER-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS
    申请人:Kühnert Sven
    公开号:US20120101079A1
    公开(公告)日:2012-04-26
    Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    6-氨基烟酰胺,含有这些化合物的药物组合物,以及这些化合物在治疗和/或预防疼痛以及其他疾病和/或紊乱中的用途。
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR AND NEUROLOGICAL DISEASES
    申请人:KANDULA Mahesh
    公开号:US20150119344A1
    公开(公告)日:2015-04-30
    The invention relates to the compounds of formula I, formula II and formula III or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II or formula III and methods for the treatment of cardiovascular and neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, postprandial hyperglycemia, depression, Alzheimer's disease, Parkinson's disease, Huntington's disease, inflammation, Crohn's disease, inflammatory bowel disease and obesity.
    该发明涉及公式I、公式II和公式III的化合物或其药用可接受的盐,以及其多晶形、溶剂合物、对映体、立体异构体和水合物。包括公式I、公式II或公式III化合物的有效量的药物组合物,以及用于治疗心血管和神经系统疾病的方法,可制备为口服、颊下、直肠、局部、经皮、经粘膜、静脉内、肠外、糖浆或注射剂。这种组合物可用于治疗高血糖、胰岛素抵抗、糖尿病、尿崩症、1型糖尿病、2型糖尿病、微血管并发症、大血管并发症、脂质紊乱、糖尿病前期、肥胖、心律失常、心肌梗死、中风、神经病变、肾脏并发症、高三酸甘油酯血症、心血管并发症、餐后高血糖、抑郁症、阿尔茨海默病、帕金森病、亨廷顿病、炎症、克罗恩病、炎症性肠病和肥胖症的治疗。
  • PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION
    申请人:Hupe Eike
    公开号:US20090156553A1
    公开(公告)日:2009-06-18
    The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.
    本发明涉及使用式(I)的哌嗪化合物或式(I)的农业有用盐作为除草剂,式(I)中的变量如权利要求书和说明书所述。
  • COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE
    申请人:Kotian Pravin L.
    公开号:US20150191472A1
    公开(公告)日:2015-07-09
    Provided are compounds of Formula I: as described herein. Compounds of Formula I are useful in methods of inhibiting viral RNA polymerase activity and viral replication. Also provided are pharmaceutical compositions comprising compounds of Formula I, as well as methods of treating viral infections using compounds of Formula I.
    提供的是式I的化合物,如本文所述。式I的化合物在抑制病毒RNA聚合酶活性和病毒复制的方法中是有用的。还提供了包含式I化合物的制药组合物,以及使用式I化合物治疗病毒感染的方法。
  • 1,5-BENZODIAZEPINE DERIVATIVES
    申请人:ZERIA PHARMACEUTICAL CO., LTD.
    公开号:EP0945445A1
    公开(公告)日:1999-09-29
    1,5-Benzodiazepine derivatives represented by formula (I), salts thereof, and medicines containing the same as the active ingredient: [wherein R1 represents a hydrogen atom, a lower alkyl group, a lower alkoxyl group, or a halogen atom; each of R2 and R3, which may be the same or different, represents a hydrogen atom, an alkenyl group, an alkyl group, a phenyl group, an acyl group, etc; and each of R4 and R5, which may be the same or different, represents a hydrogen atom, an alkyl group, a carboxyl group, etc.]. The compounds exhibit excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder.
    由式(I)代表的 1,5-苯并二氮杂卓衍生物、其盐类以及以其为有效成分的药物: [其中 R1 代表氢原子、低级烷基、低级烷氧基或卤素原子;R2 和 R3(可以相同或不同)分别代表氢原子、烯基、烷基、苯基、酰基等;R4 和 R5(可以相同或不同)分别代表氢原子、烷基、羧基等]。这些化合物具有优异的胃泌素和/或 CCK-B 受体拮抗作用,可用于治疗胃溃疡和胃肠运动紊乱。
查看更多